Drugs / FPI-2053
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06147037 | Jul 2024 → Dec 2026 expected | colorectal carcinoma, gastric cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma +2 | AstraZeneca | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07500987 Background | Feb → Jul 2026 overdue | — | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FPI-2053 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07500987 ↗ |
| Modality | Monoclonal antibody | “unconjugated/unlabelled bispecific antibody” NCT07500987 ↗ |
| Target | EGFR | “FPI-2053 is a bispecific antibody that targets EGFR” NCT06147037 ↗ |
| Target | MET | “FPI-2053 is a bispecific antibody that targets EGFR and cMET” NCT06147037 ↗ |